Nova Mentis Life Science
Market Cap
CA$14.4m
Last Updated
2021/05/07 22:48 UTC
Data Sources
Company Financials
Executive Summary
Nova Mentis Life Science Corp., through its subsidiaries, focuses on developing medicinal psychedelics for neuroinflammatory conditions with a focus on autism spectrum disorder. More Details
Snowflake Analysis
Flawless balance sheet and overvalued.
Share Price & News
How has Nova Mentis Life Science's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: NOVA is not significantly more volatile than the rest of Canadian stocks over the past 3 months, typically moving +/- 14% a week.
Volatility Over Time: NOVA's weekly volatility has decreased from 21% to 14% over the past year.
Market Performance
7 Day Return
4.0%
NOVA
-11.0%
CA Biotechs
1.9%
CA Market
1 Year Return
8.3%
NOVA
-25.0%
CA Biotechs
36.9%
CA Market
Return vs Industry: NOVA exceeded the Canadian Biotechs industry which returned -18% over the past year.
Return vs Market: NOVA underperformed the Canadian Market which returned 37.1% over the past year.
Shareholder returns
| NOVA | Industry | Market | |
|---|---|---|---|
| 7 Day | 4.0% | -11.0% | 1.9% |
| 30 Day | -3.7% | -15.0% | 2.2% |
| 90 Day | -40.9% | -22.7% | 8.3% |
| 1 Year | 8.3%8.3% | -25.0%-25.0% | 41.4%36.9% |
| 3 Year | -89.7%-89.7% | 5.0%5.0% | 30.1%17.7% |
| 5 Year | -40.9%-40.9% | 23.0%23.0% | 60.1%36.2% |
Long-Term Price Volatility Vs. Market
How volatile is Nova Mentis Life Science's share price compared to the market and industry in the last 5 years?
Simply Wall St News
5 months ago | Simply Wall St
We Think Nova Mentis Life Science (CSE:NOVA) Can Afford To Drive Business Growth10 months ago | Simply Wall St
Is Liberty Leaf Holdings (CSE:LIB) In A Good Position To Invest In Growth?1 year ago | Simply Wall St
Is Liberty Leaf Holdings (CSE:LIB) In A Good Position To Deliver On Growth Plans?Valuation
Is Nova Mentis Life Science undervalued compared to its fair value and its price relative to the market?
2.16x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate NOVA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate NOVA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: NOVA is unprofitable, so we can't compare its PE Ratio to the XN Biotechs industry average.
PE vs Market: NOVA is unprofitable, so we can't compare its PE Ratio to the Canadian market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NOVA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: NOVA is good value based on its PB Ratio (2.2x) compared to the CA Biotechs industry average (4x).
Future Growth
How is Nova Mentis Life Science forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
45.2%
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nova Mentis Life Science has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Past Performance
How has Nova Mentis Life Science performed over the past 5 years?
-49.1%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NOVA is currently unprofitable.
Growing Profit Margin: NOVA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NOVA is unprofitable, and losses have increased over the past 5 years at a rate of 49.1% per year.
Accelerating Growth: Unable to compare NOVA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NOVA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-11.6%).
Return on Equity
High ROE: NOVA has a negative Return on Equity (-493.7%), as it is currently unprofitable.
Financial Health
How is Nova Mentis Life Science's financial position?
Financial Position Analysis
Short Term Liabilities: NOVA's short term assets (CA$3.0M) exceed its short term liabilities (CA$383.0K).
Long Term Liabilities: NOVA has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: NOVA is debt free.
Reducing Debt: NOVA has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NOVA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: NOVA has sufficient cash runway for 2.5 years if free cash flow continues to reduce at historical rates of 6.6% each year.
Dividend
What is Nova Mentis Life Science current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NOVA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NOVA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NOVA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NOVA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of NOVA's dividend in 3 years as they are not forecast to pay a notable one for the Canadian market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
3.9yrs
Average management tenure
CEO
Will Rascan
9yrs
Tenure
CA$150,000
Compensation
Mr. William Rascan, also known as Will, serves as Director at 79 Resources Ltd. since December 23, 2020. Mr. Rascan has been the Chief Executive Officer of Nova Mentis Life Science Corp. (formerly known as...
CEO Compensation Analysis
Compensation vs Market: Will's total compensation ($USD123.00K) is about average for companies of similar size in the Canadian market ($USD156.56K).
Compensation vs Earnings: Will's compensation has been consistent with company performance over the past year.
Leadership Team
Experienced Management: NOVA's management team is considered experienced (3.9 years average tenure).
Board Members
Experienced Board: NOVA's board of directors are considered experienced (3 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NOVA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Ownership Breakdown
Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 245.9%.
Top Shareholders
Company Information
Nova Mentis Life Science Corp.'s company bio, employee growth, exchange listings and data sources
Key Information
- Name: Nova Mentis Life Science Corp.
- Ticker: NOVA
- Exchange: CNSX
- Founded: 2004
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: CA$14.448m
- Shares outstanding: 111.14m
- Website: https://www.novamentis.ca
Location
- Nova Mentis Life Science Corp.
- 700-838 West Hasting Street
- Vancouver
- British Columbia
- V6C 0A6
- Canada
Listings
Biography
Nova Mentis Life Science Corp., through its subsidiaries, focuses on developing medicinal psychedelics for neuroinflammatory conditions with a focus on autism spectrum disorder. It is also involved in the ...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/05/07 22:48 |
| End of Day Share Price | 2021/05/07 00:00 |
| Earnings | 2020/12/31 |
| Annual Earnings | 2020/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.